Intech Investment Management LLC Buys Shares of 12,733 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Intech Investment Management LLC purchased a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 3rd quarter, HoldingsChannel.com reports. The firm purchased 12,733 shares of the company’s stock, valued at approximately $497,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Quest Partners LLC raised its stake in shares of Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after acquiring an additional 1,127 shares during the last quarter. Amalgamated Bank grew its stake in shares of Mirum Pharmaceuticals by 60.8% in the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares during the period. ProShare Advisors LLC bought a new position in Mirum Pharmaceuticals during the 2nd quarter worth $213,000. Finally, Creative Planning acquired a new position in Mirum Pharmaceuticals during the 3rd quarter worth about $249,000.

Insiders Place Their Bets

In related news, SVP Jolanda Howe sold 2,500 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00. Following the transaction, the senior vice president now directly owns 2,426 shares in the company, valued at $114,264.60. The trade was a 50.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 22.87% of the stock is owned by company insiders.

Mirum Pharmaceuticals Trading Down 0.9 %

Shares of Mirum Pharmaceuticals stock opened at $46.22 on Monday. The company’s fifty day simple moving average is $40.93 and its 200-day simple moving average is $37.49. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $48.89. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The stock has a market capitalization of $2.22 billion, a PE ratio of -22.88 and a beta of 1.16.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. During the same quarter last year, the business posted ($0.57) EPS. The firm’s revenue for the quarter was up 89.4% compared to the same quarter last year. As a group, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Cantor Fitzgerald lifted their price objective on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. Evercore ISI upped their target price on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Citigroup raised their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Leerink Partners boosted their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, Robert W. Baird raised their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $57.73.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.